Alteration in Disposition Kinetics of Warfarin Mediated by Caffeine in Healthy Male Albino Rabbits. | [Journal of Animal and Plant sciences • 2019]

Author(s):

1. S Zafar: Department of Physiology, Government College University, Faisalabad, Pakistan: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

2. A Ali: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

3. MM Ashraf: Department of Eastern Medicine, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

4. JA Khan: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

5. B Aslam: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

6. RD Naseer: Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan

Abstract:

Many physicians are afraid of being involved in allegation of malpractices due to occurrence of severe drug interactions. These interactions not only occur between drugs but also between any kind of food, tobacco smoke, caffeine and alcohol etc. Therefore, current study was conducted to inspect the effect of caffeine on the disposition kinetics of warfarin in ten healthy adult male albino rabbits. Blood samples were collected at same time intervals after administration of warfarin (0.5 mg.kg-1) alone and then in its combination with caffeine (5 mg.kg-1 every twelve hours for three days) following a washout period of 14 days in each rabbit. Warfarin concentration in plasma was measured by high performance liquid chromatographic (HPLC) technique to determine pharmacokinetic parameters. Paired t-test was applied on data for its statistical comparison. Plasma concentration values of warfarin enhanced significantly at each time interval after its coadministration with caffeine. Significant increase was observed in Kabs (from 0.4±0.0 hr-1 to 0.5±0.0 hr-1), t1/2²(from 34.1±4.8 hr to 49.1±2.4 hr), AUC (from 109.3±10.6 µg.h.mL-1 to 147.2±6.4 µg.h.mL-1) and MRT (from 52.1±6.7 hr to 72.9±3.4 hr) of warfarin after its concomitant administration with caffeine. Whereas, a significant decrease in t1/2abs (from 2.0±0.2 hr to 1.5±0.1 hr), ² (from0.03±0.0 hr-1 to 0.01±0.0 hr-1) and ClB (from 0.01±0.0 L.hr-1kg-1 to 0.004±0.0 L.hr-1kg1) of warfarin was observed after its combination with caffeine. Caffeine slows down the biotransformation of warfarin resulting in reduced elimination of warfarin which leads to increased concentration of warfarin within the body. Thus, anticoagulant activity of warfarin may enhance in combination with caffeine. So, clinicians should avoid or be cautious while using caffeine during warfarin therapy to avoid any mishap or unwanted event.

Page(s): 158-165

DOI: DOI not available

Published: Journal: Journal of Animal and Plant sciences, Volume: 29, Issue: 1, Year: 2019

Keywords:

Keywords are not available for this article.

References:

[1] Anwar , M.,B.Aslam,M.M.Ashraf,A . Raza, 2015.Renal clearance and urinary excretion of cefspan® in healthy male volunteers,Scholar s Adv. Anim. Vet. Res 2 117 -22

[2] Ashraf , M.M.,I.Javed,B.Aslam,T.Khaliq, 2015.Disposition kinetics and bioavailability comparison of two formulations of cefixime in healthy adult male subjects,Professional Med. J 22 959 -965

[3] Aziz , A.,BAslam,M.M. Ashraf , U.,Naz , N.,Ashraf , A.,Raza , A.,Sarwar and F.,Sarwar, 2016.Pharmacokinetic study of glimepiride alone and in combination with atorvastatin in healthy male volunteers,Lat. Am. J. Pharm 35 2331 -2336

[4] Bielesz , K.,W.Strzelczyk,M.Poniewaz,F.SokoBowski,D.Welsyng,M.,Nawrocki, 2013.The effect of coffee on blood pressure at healthy subjects,Pol. Merkur. Lekarski 35 133 -135

[5] Bjornsson , T.D., T.F.,Blaschke and P.J.,Meffin, 2006.High-pressure liquid chromatographic analysis of drugs in biological fluids I: Warfarin,J. Pharm. Sci 66 142 -144

[6] Dieterle , W., S.,Corynen,Mann, 2004.Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects,Br. J. Clin. Pharmacol 58 433 -436

[7] Eugster , H.,M.Probst,F.E.Würgler,C.Sengstag, 1993.Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2: Evidence from cDNA-directed expression in Saccharomyces cerevisiae,Drug Metab. Dispos 21 43 -49

[8] Fayyaz , A.,J.A.Khan,M.M. Ashraf , N.,Akhtar , B.,Aslam , M.F.,Khalid , S.,Altar , R.D.,Nasser , M.,Akram , S.M.A.,Shah , M.W.,Khadam and I.M.,Tahir, .Pharmacokinetic behavior of Montelukast in indigenous healthy male volunteers,Pakistan J. Pharm. Sci 30 2435 -2439

[9] Gonzalez , F.J.,R.H.Tukey, 2010.Goodman and Gilman's The Pharmacological Basis of Therapeutics,McGraw Hill -

[10] Holbrook , A.M.,J.A.Pereira,R.Labiris,H.McDonald,J.D.Douketis,P.S.Wells, 2005.Systematic overview of warfarin and its drug and food interactions,Arch. Intern. Med 165 1095 -1106

[11] Julkunen , R.J.,M.Kekki,B.Wahlström, 1980.A model solution for intestinal absorption of warfarin. A drug with non-linear distribution pharmacokinetics in the rat,Arzneimittelforschung 30 264 -267

[12] Kaminsky , L.S.,Z.I. Zhang, 1997.Human P450 metabolism of warfarin,Pharmacol. Therap 73 67 -74

[13] Kot , M.,DanielW.A, 2008.The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms,Biochem. Pharmacol 76 543 -551

[14] Kwon , M.J.,H.J.Kim,J.W.Kim,K.H.Lee,K.H.Sohn,H.J.Cho,Y.K.On,J.S.Kim,S.Y.Lee, 2009.Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application,Korean J. Lab Med 29 515 -523

[15] Lane , S. , S.,Al-Zubiedi , E.,Hatch , I. Matthews,A.L.Jorgensen,P.Deloukas,A.K.Daly,B.K.Park,L.Aarons,K.Ogungbenro,F.Kamali,D.Hughes,M.Pirmohamed, 2012.The population pharmacokinetics of R- and Swarfarin: effect of genetic and clinical factors,Br. J. Clin. Pharmacol 73 66 -76

[16] Lindh , J.D.,L.Holm,L.A.Marine,A . Rane, 2009.Influence of CYP2C9 genotype on warfarin dose requirements: a systematic review and metaanalysis,Eur. J. Clin. Pharmacol 65 365 -

[17] Lomonaco , T., S.,Ghimenti , I. Piga, M.,Onor , B.,Melai , R.,Fuoco and F.D.,Francesco, 2013.Determination of total and unbound warfarin and warfarin alcohols in human plasma by high performance liquid chromatography with fluorescence detection,J. Chromatogr 1314 54 -62

[18] Majerus , P.W.,D.M. Tollefsen, 2010.Goodman and Gilman's the pharmacological basis of therapeutics,McGraw Hill -

[19] Nagui , J.S.,Q.Chen,M.Shou,R.W.Wang,R.A.Stearns,T.A.Baillie,W.Tang, 2001.In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarinby in Drug metabolism and disposition: the biological fate of chemicals,Drug Metab. Dispos 29 877 -886

[20] Naz , U.,M.M. Ashraf , I.,Javed , B.,Aslam , J.A.,Khan , F.,Muhammad , T.,Khaliq , Z.U.,Rahman , H.,Anwar , N.,Ashraf , A.,Raza and M.,Naeem, 2017.Comparative pharmacokinetics of cefspan and ceforal-3 in adult human healthy female subjects,Lat. Am. J. Pharm 36 776 -782

[21] Neutescu , E.A.,N.L.Shapiro,S.Ibrahim,P.West, 2006.Warfarin and its interactions with food, herbs and other dietry suppliments,Expert Opin. Drug Saf 5 433 -451

[22] Palareti , G. and C.,Legnani, 1996.Warfarin withdrawal: Pharmacokinetic-pharmacodynamic considerations,Clin. Pharmacokinet 30 300 -313

[23] Patui , S.,L.Clincon,C.Peresson,M.Zancani,L.Conte,L.D.Terra,L.Navarini,A.Vianello,Braidot, 2014.Lipase activity and antioxidant capacity in coffee seeds during germination,Plant Sci 219 19 -25

[24] Preissner , S.,K.Kroll,M.Dunkel,C.Senger,G.Goldsobel,D.Kuzman,S.Guenther,R.Winnenburg,M.Schroeder,R.Preissner, 2010.SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions,Nucleic Acids Res 38 D237 -D243

[25] Sachse , C.,J. Brockmöller , S.,Bauer and I. Roots, 1999.Functional significance of a CA polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine,Br. J. Clin. Pharmacol 47 445 -449

[26] Sana , T.,B.Aslam,N.Aslam,M.M. Ashraf , A.,Ashraf , T.A.,Mailk , S.G.,Niazi , I.M.,Tahir , M.R.,Rahman,Ahmad, 2016.Therapeutic effect of atorvastatin on kidney functions and urinary excretion of glimepiride in healthy adult human male subjects,Pakistan J. Pharm. Sci 29 2321 -2326

[27] Shehzad , A.,B.Aslam,U.Naz,M.M. Ashraf , N.,Aslam , U.,Saleem , S.,Kausar,Naeem, 2017.Pharmacokinetics and Dosage Regimen of Moxifloxacin in Healthy Female Volunteers,Lat. Am. J. Pharm 36 2196 -2202

[28] Steel , R.G.D.,J.H.Torrie,D.A.Dicke, 1997.Principles and procedures of statistics: A biometrical approach,McGraw Hill series in probability and statistics 284 -351

[29] Sun , S.,M.Wang,L.Su,J.Li,H.Li,D.Gu, .Study on warfarin plasma concentration and its correlation with international normalized ratio,J. Pharm. Biomed. Anal 42 218 -222

[30] Walker , G.,A.Mandagere,C.Dufton,Venitz, 2009.The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers,Br. J. Clin. Pharmacol 67 527 -534

[31] Zafar , S.,M.M. Ashraf , A.,Ali , N.,Aslam , A.,Ashraf , S.,Zafar , R.,Andleeb , M.W.,Khadam , I.M.,Tahir , M.,Akram , S.M. Ali,Shah and M.,Daniyal, 2018.Effect of caffeine on anti-clotting activity of warfarin in healthy male albino rabbits,Pakistan J. Pharm. Sci 31 611 -616

Citations

Downloads

Views